Yoga-CaRe Heart Failure Trial in Chicago, Illinois: 3,492 Patients Gained 8.1 Quality-of-Life Points and 25.5 Metres on the Six-Minute Walk at Three Months, With No Significant Difference in Death, Hospitalization or Stroke at 21.0% Versus 22.8%
CHICAGO, Cook County, Illinois — Results of the Yoga-CaRe HF trial, presented on November 7 at the American Heart Association's Scientific Sessions 2026 in Chicago, showed that a supervised yoga-based cardiac rehabilitation programme improved quality of life and walking capacity in patients with heart failure with reduced ejection fraction (HFrEF), but did not significantly reduce the combined rate of death, hospitalization or stroke. According to the meeting coverage, the trial randomized 3,492 adults at 16 medical centres in India — 1,737 to the yoga group and 1,755 to enhanced standard care — recruiting between April 2023 and December 2025, including patients with an ejection fraction of 40% or below and patients hospitalized for acute decompensated heart failure.
The yoga group received written health education on living well with heart failure, guided behaviour change and goal-setting assistance, plus 20 supervised sessions over three months combining in-person, virtual and at-home instruction. At three months, the yoga group's Minnesota Living with Heart Failure Questionnaire scores improved by about 8.1 points more than the control group's, participants walked an average of 25.5 metres farther on the six-minute walk test, and the mean difference in EQ-5D utility score was 0.05, with P<0.001 reported for all three comparisons. Over a median follow-up of 15 months, 21.0% of the yoga group and 22.8% of the control group reached the composite endpoint of death, hospitalization or stroke — a hazard ratio of 0.90 that was not statistically significant, so that co-primary endpoint was not met.
The study was presented by Dorairaj Prabhakaran, M.B.B.S., M.D., D.M., executive director of the Centre for Chronic Disease Control in India, with Ambalam Chandrasekaran reporting the late-breaking science. The American Heart Association notes that abstracts presented at its scientific meetings are not peer-reviewed and that findings are considered preliminary until published in a peer-reviewed journal. This report presents only the trial data and the investigators' statements and does not constitute medical advice for any individual.
来源链接：美国心脏病学会会议报道（acc.org）： https://www.acc.org/latest-in-cardiology/articles/2026/11/06/14/37/sat-5pm-yoga-aha-2026 ；试验报道（tctmd.com）： https://www.tctmd.com/news/yoga-care-qol-and-functional-gains-seen-hfref-patients
Source: American Heart Association
Published by GSM · USA (original Chinese edition)
Photo: 图：瑜伽课堂。Yogacharya Rajendra 摄，CC BY-SA 4.0，经 Wikimedia Commons。 / Photo: A yoga class. Photo by Yogacharya Rajendra, CC BY-SA 4.0, via Wikimedia Commons.
OPTIMAL-DIABETES Trial at AHA Scientific Sessions in Chicago, Illinois: Intensive Blood Pressure Target Below 120 Did Not Significantly Cut Cardiovascular Events in 9,476 Adults With Type 2 Diabetes, 6% Versus 6.7%2026-11-08
At the AHA Sessions in Chicago, Illinois, a November 8 Poster on Evategrel: Chinese and U.S. Participants Showed Comparable Pharmacokinetics and Pharmacodynamics, and Food Slowed Absorption but Not Total Exposure2026-11-08